WO2014052225A1 - Composition for prostatic hyperplasia and prostate cancer - Google Patents
Composition for prostatic hyperplasia and prostate cancer Download PDFInfo
- Publication number
- WO2014052225A1 WO2014052225A1 PCT/US2013/061143 US2013061143W WO2014052225A1 WO 2014052225 A1 WO2014052225 A1 WO 2014052225A1 US 2013061143 W US2013061143 W US 2013061143W WO 2014052225 A1 WO2014052225 A1 WO 2014052225A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tea
- composition
- extracts
- prostate
- prostate cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 206010060862 Prostate cancer Diseases 0.000 title description 19
- 208000000236 Prostatic Neoplasms Diseases 0.000 title description 18
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title description 7
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title description 7
- 244000269722 Thea sinensis Species 0.000 claims abstract description 53
- 235000013616 tea Nutrition 0.000 claims abstract description 29
- 240000006661 Serenoa repens Species 0.000 claims abstract description 18
- 239000010018 saw palmetto extract Substances 0.000 claims abstract description 15
- 235000005318 Serenoa repens Nutrition 0.000 claims abstract description 14
- 208000017497 prostate disease Diseases 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 229930014626 natural product Natural products 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 6
- 239000000284 extract Substances 0.000 claims description 34
- 235000006468 Thea sinensis Nutrition 0.000 claims description 16
- 235000020279 black tea Nutrition 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 150000004665 fatty acids Chemical class 0.000 claims description 10
- 235000009569 green tea Nutrition 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 9
- 150000007513 acids Chemical class 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 3
- 229940063845 saw palmetto extract Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 7
- 206010020718 hyperplasia Diseases 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- -1 tea Natural products 0.000 abstract description 4
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 235000013311 vegetables Nutrition 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 239000010775 animal oil Substances 0.000 abstract description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract description 2
- 239000008158 vegetable oil Substances 0.000 abstract description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 19
- 235000013824 polyphenols Nutrition 0.000 description 19
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000003098 androgen Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 235000020688 green tea extract Nutrition 0.000 description 6
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 5
- 229940030486 androgens Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 241000200478 Prunus africana Species 0.000 description 4
- 235000000719 Prunus africana Nutrition 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000911175 Citharexylum caudatum Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 235000014676 Phragmites communis Nutrition 0.000 description 3
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 3
- 102000001854 Steroid 17-alpha-Hydroxylase Human genes 0.000 description 3
- 108010015330 Steroid 17-alpha-Hydroxylase Proteins 0.000 description 3
- 241000245665 Taraxacum Species 0.000 description 3
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000001448 anilines Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000177 juniperus communis l. berry Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 230000037209 prostate health Effects 0.000 description 3
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 3
- 235000014620 theaflavin Nutrition 0.000 description 3
- 102100032187 Androgen receptor Human genes 0.000 description 2
- 241000508725 Elymus repens Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010051482 Prostatomegaly Diseases 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940026509 theaflavin Drugs 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-HIFRSBDPSA-N (-)-catechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-HIFRSBDPSA-N 0.000 description 1
- 229930013799 (-)-catechin Natural products 0.000 description 1
- 235000007331 (-)-catechin Nutrition 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 101100497948 Caenorhabditis elegans cyn-1 gene Proteins 0.000 description 1
- 241000209507 Camellia Species 0.000 description 1
- 235000014143 Camellia sinensis var assamica Nutrition 0.000 description 1
- 240000008441 Camellia sinensis var. assamica Species 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100036881 Inositol-3-phosphate synthase 1 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- AFIHOCXPBZMOEO-UHFFFAOYSA-N POOS Chemical compound POOS AFIHOCXPBZMOEO-UHFFFAOYSA-N 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- CXQWRCVTCMQVQX-UHFFFAOYSA-N cis-dihydroquercetin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-UHFFFAOYSA-N 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229940046528 grass pollen Drugs 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960000249 pregnenolone Drugs 0.000 description 1
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008171 pumpkin seed oil Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
Definitions
- This invention relates to a composition and method for the treatment of prostate diseases, such as, benign prosthetic hyperplasia, hereinafter referred to as "BPH " .
- Benign proetatsc hyperplasia or 8PH a gradual enlargement of the prostate, Is the most common benign proliferative disorder of unknown etiology found in men, affecting- at least 80% of all men over age 50 years old. An enlarged prostate Is not cancer. There is no evidence that BPH leads to prostate cancer. However, symptoms of both disorders are similar, and it is possible to have BPH and prostate cancer at the same time. Deregulation of testosterone's conversion to dmydrotesfosterone (DHT) by 5 alpha-reductase Is the key step in the development of BPH.
- DHT dmydrotesfosterone
- Elevated DHT ievels correlate with the pathogenesis and progression of androgen-dependent diseases such as prostate cancer and BPH.
- the relationship between prostate cancer and androgens is concluded to be U-shaped, with both extremes of androgen concentrations being associated with increased risk of invasive cancer.
- 8PH has been treated with Sa-reductase inhibitors such as sa palmetto extracts, In which the conversion of testosterone to DHT Is blocked. Hence, the DHT ievei available to prostate tissue Is lowered.
- Drugs for BPH treatment also include alpha-adrenerglc receptor
- dietary supplements for promoting prostate health include horbal agents saw palmetto extracts (SPEp rye grass pollen extract, pygeum, lycopone from tomato (peel) extraels : and extracts from
- EC1. 14 99,9 EC4. 1.2.30 is the microsomal cytochrome P45G-dep@ndeni rnono-oxygenase which catalyzes doth l/a-hydroxylation and ciaavage of the C1?,20-3 ⁇ 4ide chain during the conversion of 21 -carbon steroids pregnenolone (human) and progesterone (rat) to the 19-carbon androgens
- the present invention comprises compositions of compounds which are useful for promoting prostate health, treating prostate diseases Including enlarged prostate, prostatitis, benign prosthetic hyperplasia and prostate cancer.
- the com osition of the present invention may be obtained either by ⁇ 1 ⁇ extraction from natural products such as tea, saw palmetto, fruits and/or vegetables as weii as animal and vegetable oils or (2) by chemical synthesis from compounds o tained from natural products. More particularly, the synthesized compounds of the invention are obtained from the chemical or enzymatic reaction between fatty acids and polyphenols or benzotroplone derivative that have phenolic groups to produce esters which exhibit the properties of the Inventive composition.
- the inventive compositions are administered to a human subject diagnosed with/and or suffering from a prostate disease in an anti-prostate disease effective amount of the inventive composition.
- the natural product combination of the present Invention preferably is comprised of tea extracts and sa palmetto extracts.
- Suitable tea extracts include green tea extracts, black tea extracts or both.
- the efficacious compounds in tea extracts are tea polyphenols including green tea
- Suitable black tea polyphenols Include thea iavlns and ihearub!gins..
- Theaflav!ns include theaflavin (TFI) ; theaflavln-B-monogailte (IF 2a or TF2, ⁇ S f eaflavsn-3' «moncgai!ate CTF2b or TF2h, theafIavin-3,3 -digallate ⁇ TF3) 5 isotheaflavins, theaflagaliins. fbeafiavates, fheaiiavlc acids, theanap thoquinone.
- Theafubigins include bistheaflavins t thead;ben£otroplones : theatribenzotropoiones ; dehydrotheatlavins, EGCG dlmer and oiicopolymers, Iheasinensins., and atheogallimn.
- POISJ Green tee eatechins and black tea theafiavins can inhibit CYP1 , and or Inhibit both CYP17 and Sa ⁇ reductase ; which consequently inhibit the production of testosterone and DHT that are responsible for prostate cancer promotion.
- the green tea component EGCG end black tea component Theaflavln-3-O-monoqallate can in ibi human prostate carcinoma INCaP cells.
- a recent double-blind study far 200 individuals was carried out wherein 100 individual took SOOmq of green tea polyphenols and another 100
- PC!ITJ Tea polyphenols particularly EGCG, EGG. EC in green tea extracts and black tea polyphenols such as theaflavins ; i.e. Theaflsvin, Tfteafiavin-3- monogallate i Theafiavin-S'-- monogai!ate and ThealiavlmS ⁇ -dsgailate etc b nzotropofone derivatives have strong anil- Inflammatory activity Tea polyphenols can down-regulate the expression of Cox-2, INOS, TNF-a. MFKS, IU. IL-8, lL-8 ( ICA&M , p53, im ki ase, AP-i Inflammation genes and inhibit protein activity. Also, tea polyphenols can induce cancer cell apoptosis.
- tea polyphenols can induce cancer cell apoptosis.
- 100183 Saw palmetto extracts suitable for use in the present invention ma be obtained by the extraction of saw palmetto berry, leaves and plants using both organic and water as solvents such as ethyl acetate, ettianol, methanol liquid carbon dsoxlde, acetone or mixtures of solvents.
- esters has the formula:
- the polyphenols may be from EC EGG, EGG, EGCG, GC 5 GCG
- the fatty acids may be from saw palmetto (including lauric acid, n nstic acid, palmitic sold, stearic acid, eapric acid, caprylic acid, oleic acid, fin ieic acid. Unolenlo acid, and other fatty acids and fatty alcohols and sterols in saw palmetto), pygeum, folium urtloae, dandelion, juniper berry, rhisome phragrnifls (reed root). couehgrass, coucngrass root (tea root; and fatty acids from other plant extracts.
- saw palmetto including lauric acid, n nstic acid, palmitic sold, stearic acid, eapric acid, caprylic acid, oleic acid, fin ieic acid. Unolenlo acid, and other fatty acids and fatty alcohols and sterols in saw palmet
- the compounds synthesized also include the esters formed from fatty acids and enzotropione derivatives that have phenolic group(s).
- esters include mixtu e of esters formed by treating tea extracts and saw palmetto extracts in a certain ratio with acids and or enzymes that can catalyze the ester synthesis,
- the polyphenols also Include flavonosds, such as f avonolds from fruits, for example, apple, citrus fruits and citrus peels, blue berry, and cranberry, and/or vegetables, such as, onion, broccoli, tomato, carrots and the like.
- flavonosds such as f avonolds from fruits, for example, apple, citrus fruits and citrus peels, blue berry, and cranberry
- vegetables such as, onion, broccoli, tomato, carrots and the like.
- the sources of fatty acids include sa palmetto, pygeum, folium
- amines and anilines also can be used to synthesize amides from fatty acids and these amines and anilines, such as celliam;ne from Rhixoma phragmltis.
- the combination formulas composed of combination of tea extracts and other one or more plant extracts .e.g., saw palmetto extracts, the formed compounds (esters and amides) between the fatty acids and polyphenols (and also amines and anilines from some plants) can promote prostate health and treat prostate diseases including enlarged prostata, prostatitis, benign prostatic hyperplasia ⁇ BPH ⁇ and prostate cancer,
- the resulting combination formula is expected to treat BPH and prevention and treatment of prostata cancer by s nsrglstiealy inhibiting Sa-reductase by saw palmetto extracts and tea polyphenols; b inhibiting CYP17 f17a-hydroxyiase/C1T ; 20- lyase) by thea!lsylns and thearubiglns m black tea extracts and eatechins in green tea extracts; by inhibiting the growth of prostate cancer celis ⁇ LNCaP) and further decreasing the level of androgen receptor and the decrease of PSA secretion: and by strong anthlnflammatlon and apoptotic activity of tea polyphenols,
- the extract may be prepared by extraction from water, eihanoL mixture of water and ethanol, ethyl acetate., methanol or mix ure of methanol and water.
- the extraction Is carried out for rom 5-60 minutes and repealed 2-3 times.
- the extraction temperature range from ambient temperature to 100 °C. the temperature as even higher, 120 e C to 140 ; € when pressure was applied In the extraction process.
- the pressure can be as high as 100 aim (1500 psl).
- composition of the invention may be administered to a human subject diagnosed with a prostate disease in an antlprostate disease effective amount by Intravenous injection, subcutaneous injection, intramuscular Injection , topical application, oral administration in liquid or tablet form or other conventions forms of medicinal administration, e.g., nasal injection or inhalation via drops or spray..,
- An Important aspect in treating BPH and prostate cancer prevention and treatment is the combination of tea ⁇ black tea and green tea) extracts and saw palmetto extracts m various proportions., suet; as 10%-9S
- Tea extracts can be green tea extract , black tea extracts or the mixture of green tea extracts and black, tea extracts ;n various proportion of each tea extracts
- the tea polyphenols, or catechsn content of green tea extracts range from I %-99% and the content of theaiiavins in black tea extracts range f om S%- 90%.
- Black tea extracts can contain thearublgins range from 5% ⁇ 80%. All proportions expressed herein are on a weight/weight basis.
Abstract
A composition and method for the treatment of prostate diseases, such as, benign prosthetic hyperplasia, hereinafter referred to as "BΡΗ" is disclosed. The composition of the present invention may be obtained either by (1) extraction from natural products such as tea, saw palmetto, fruits and/or vegetables as well as animal and vegetable oils or (2) by chemical synthesis from compounds obtained from natural products. Methods for preparing and using the inventive composition are also disclosed.
Description
COMPOSITION FOR PROSTATIC HYPERPLASIA AND PROSTATE CANCER
10 031 (1 ) F eld of the Invention
[ 0041 This invention relates to a composition and method for the treatment of prostate diseases, such as, benign prosthetic hyperplasia, hereinafter referred to as "BPH".
POOS] (2) Description of Related Art
0)006] Benign proetatsc hyperplasia or 8PH, a gradual enlargement of the prostate, Is the most common benign proliferative disorder of unknown etiology found in men, affecting- at least 80% of all men over age 50 years old. An enlarged prostate Is not cancer. There is no evidence that BPH leads to prostate cancer. However, symptoms of both disorders are similar, and it is possible to have BPH and prostate cancer at the same time. Deregulation of testosterone's conversion to dmydrotesfosterone (DHT) by 5 alpha-reductase Is the key step in the development of BPH. Elevated DHT ievels correlate with the pathogenesis and progression of androgen-dependent diseases such as prostate cancer and BPH. The relationship between prostate cancer and androgens is concluded to be U-shaped, with both extremes of androgen concentrations being associated with increased risk of invasive cancer. 8PH has been treated with Sa-reductase inhibitors such as sa palmetto extracts, In which the conversion of testosterone to DHT Is blocked. Hence, the DHT ievei available to prostate tissue Is lowered.
[000?! Drugs for BPH treatment also include alpha-adrenerglc receptor
blockers. Up to now, dietary supplements for promoting prostate health
include horbal agents saw palmetto extracts (SPEp rye grass pollen extract, pygeum, lycopone from tomato (peel) extraels: and extracts from
pomegranates.
|0008J Recent studies show t at tea extracts exhibit anti-cancer properties against prostate cancer. The growth of prostate cancer is dependent of male sex hormones, such as testosterone and 5a~dlhydrotesiostefone (DH ), The known treatment of prostate cancer Is generally an effort to block the synthesis and action of androgens. In the biosynthesis of androgens, a crucial enzyme, 17a- hydroxyiase/Cl / JOPyase (CYP17,
EC1. 14 99,9 EC4. 1.2.30), is the microsomal cytochrome P45G-dep@ndeni rnono-oxygenase which catalyzes doth l/a-hydroxylation and ciaavage of the C1?,20-¾ide chain during the conversion of 21 -carbon steroids pregnenolone (human) and progesterone (rat) to the 19-carbon androgens
dehyoroaplandrosterone and androstenedscne; respectively. Current drug and surgery treatments are directed to eliminating testosterone production which Is about (90%) from testes out not that produced Py the adrenal route { 10%}.
! Sum a ^^^
|O01 C¾ We have discovered a composition which exhibits strong protective eftectsfcr prostate and effectively cure prostate diseases such as benign prostatic hyperplasia (8PH) and prostate cancer. Mere particularly, the present invention comprises compositions of compounds which are useful for promoting prostate health, treating prostate diseases Including enlarged prostate, prostatitis, benign prosthetic hyperplasia and prostate cancer.
O011] The com osition of the present invention may be obtained either by {1} extraction from natural products such as tea, saw palmetto, fruits and/or vegetables as weii as animal and vegetable oils or (2) by chemical synthesis from compounds o tained from natural products. More particularly, the synthesized compounds of the invention are obtained from the chemical or enzymatic reaction between fatty acids and polyphenols or benzotroplone derivative that have phenolic groups to produce esters which exhibit the properties of the Inventive composition.
{0812] In the method of the present invention, the inventive compositions are administered to a human subject diagnosed with/and or suffering from a prostate disease in an anti-prostate disease effective amount of the inventive composition.
| δΊ | The natural product combination of the present Invention preferably is comprised of tea extracts and sa palmetto extracts. Suitable tea extracts Include green tea extracts, black tea extracts or both. The efficacious compounds in tea extracts are tea polyphenols including green tea
polyphenols and black tea polyphenols. Green tea polyphenols suitable for use in the present invention Include catechins such as ( )-catechin; {-)- catechin. epicatechln (EC), eplgallocatechln (EGC): eplcateohln gallte (EGG), epigallocatechin gai!ate iEGCG), gailocatechin (GC gallocateehln gailate (GCG), catechin vallate (CG) and gallic acid. Suitable black tea polyphenols Include thea iavlns and ihearub!gins.. Theaflav!ns include theaflavin (TFI); theaflavln-B-monogailte (IF 2a or TF2,}S f eaflavsn-3'«moncgai!ate CTF2b or TF2h, theafIavin-3,3 -digallate {TF3)5 isotheaflavins, theaflagaliins.
fbeafiavates, fheaiiavlc acids, theanap thoquinone. and methylated theaflavin derivatives etc that have a common com of he bensoiropo!eme s ruc ural moiety, Theafubigins Include bistheaflavinst thead;ben£otroplones: theatribenzotropoiones; dehydrotheatlavins, EGCG dlmer and oiicopolymers, Iheasinensins., and atheogallimn.
POISJ Green tee eatechins and black tea theafiavins can inhibit CYP1 , and or Inhibit both CYP17 and Sa~reductase; which consequently inhibit the production of testosterone and DHT that are responsible for prostate cancer promotion. Also the green tea component EGCG end black tea component Theaflavln-3-O-monoqallate can in ibi human prostate carcinoma INCaP cells. A recent double-blind study far 200 individuals was carried out wherein 100 individual took SOOmq of green tea polyphenols and another 100
Individuals took a placebo. After 12 months, only 3% of patients In the green tea catechin group developed prostate cancer, whereas the rate of cancer development m the placebo taking Individuals was 30%. This study clearly showed the in vivo efficacy of green tea eatechins for prostate cancer prevention effect,
1001 SJ Theatlavins In black tea; especially Theaflavm-3.3! digaHatei were found to inhibit Sa- reductasehand cause an associate decrease In the growth OfLNCaP prostate cancer cells, which are sensitive to androgens. With black tea consumption, decrease In androgen receptor level and decrease in secretion of prostate specific antigen (PSA) was observed.
PC!ITJ Tea polyphenols, particularly EGCG, EGG. EC in green tea extracts and black tea polyphenols such as theaflavins; i.e. Theaflsvin, Tfteafiavin-3- monogallatei Theafiavin-S'-- monogai!ate and ThealiavlmS^-dsgailate etc
b nzotropofone derivatives have strong anil- Inflammatory activity Tea polyphenols can down-regulate the expression of Cox-2, INOS, TNF-a. MFKS, IU. IL-8, lL-8( ICA&M , p53, im ki ase, AP-i Inflammation genes and inhibit protein activity. Also, tea polyphenols can induce cancer cell apoptosis.
100183 Saw palmetto extracts suitable for use In the present invention ma be obtained by the extraction of saw palmetto berry, leaves and plants using both organic and water as solvents such as ethyl acetate, ettianol, methanol liquid carbon dsoxlde, acetone or mixtures of solvents.
1001 ¾ This natural product combination formula Includes comprised tea
extracts, sa palmetto extracts, pygeum, folium urtloae, dandelion, juniper berry, rhixome phragmltis (reed root), couchgrass, and couchgrass root (tea root). An ester formed from the chemical reaction or enzymatic reaction between tea polyphenols and fatty acids are esters has the formula:
[0 03 The polyphenols may be from EC EGG, EGG, EGCG, GC5 GCG
green tea eafec ns, ΤΡ TF2a If 2b TP 3, theaflavina. The fatty acids may be from saw palmetto (including lauric acid, n nstic acid, palmitic sold, stearic acid, eapric acid, caprylic acid, oleic acid, fin ieic acid. Unolenlo acid, and other fatty acids and fatty alcohols and sterols in saw palmetto), pygeum, folium urtloae, dandelion, juniper berry, rhisome phragrnifls (reed root).
couehgrass, coucngrass root (tea root; and fatty acids from other plant extracts.
[0021] The compounds synthesized also include the esters formed from fatty acids and enzotropione derivatives that have phenolic group(s).
[§S2¾ The esters include mixtu e of esters formed by treating tea extracts and saw palmetto extracts in a certain ratio with acids and or enzymes that can catalyze the ester synthesis,
023 The polyphenols also Include flavonosds, such as f avonolds from fruits, for example, apple, citrus fruits and citrus peels, blue berry, and cranberry, and/or vegetables, such as, onion, broccoli, tomato, carrots and the like.
[00241 The sources of fatty acids include sa palmetto, pygeum, folium
urticae, dandelion, juniper berry, rhizome pnrsgmiils (reed root), couohgrass, couohgrass root (te root), coffee (ohlorogenlc acids and csffelc acids etc), fish oil, pumpkin seed oils, te ,e.g,, gallic acid and the like,
|0S2Sj Besides polyphenols, some amines and anilines also can be used to synthesize amides from fatty acids and these amines and anilines, such as celliam;ne from Rhixoma phragmltis.
[0020] The combination formulas composed of combination of tea extracts and other one or more plant extracts .e.g., saw palmetto extracts, the formed compounds (esters and amides) between the fatty acids and polyphenols (and also amines and anilines from some plants) can promote prostate health and treat prostate diseases including enlarged prostata, prostatitis, benign prostatic hyperplasia {BPH} and prostate cancer,
[002?] By combining the saw palmetto extracts and tea extracts, the resulting combination formula is expected to treat BPH and prevention and treatment of
prostata cancer by s nsrglstiealy inhibiting Sa-reductase by saw palmetto extracts and tea polyphenols; b inhibiting CYP17 f17a-hydroxyiase/C1T;20- lyase) by thea!lsylns and thearubiglns m black tea extracts and eatechins in green tea extracts; by inhibiting the growth of prostate cancer celis{LNCaP) and further decreasing the level of androgen receptor and the decrease of PSA secretion: and by strong anthlnflammatlon and apoptotic activity of tea polyphenols,
fSOtS] Different species of green tea (Camellia ssnensis)may be used to
prepare the inventive oo nposion, These include Chinese tea. Camellia sinensis vat. sinensis, and , Assam tea. Camellia sinensis var. assarnlca.
|0Θ2§] The extract may be prepared by extraction from water, eihanoL mixture of water and ethanol, ethyl acetate., methanol or mix ure of methanol and water. The extraction Is carried out for rom 5-60 minutes and repealed 2-3 times. The extraction temperature range from ambient temperature to 100 °C. the temperature as even higher, 120 eC to 140 ;€ when pressure was applied In the extraction process. The pressure can be as high as 100 aim (1500 psl).
O03 ¾ The composition of the invention may be administered to a human subject diagnosed with a prostate disease in an antlprostate disease effective amount by Intravenous injection, subcutaneous injection, intramuscular Injection , topical application, oral administration in liquid or tablet form or other conventions forms of medicinal administration, e.g., nasal injection or inhalation via drops or spray..,
18031] An Important aspect in treating BPH and prostate cancer prevention and treatment is the combination of tea {black tea and green tea) extracts and
saw palmetto extracts m various proportions., suet; as 10%-9S
(welghi/ elg t) saw palmetto and 90%- 5% ( e;oht/weig t) tea extracts. Tea extracts can be green tea extract , black tea extracts or the mixture of green tea extracts and black, tea extracts ;n various proportion of each tea extracts The tea polyphenols, or catechsn content of green tea extracts range from I %-99% and the content of theaiiavins in black tea extracts range f om S%- 90%. Black tea extracts can contain thearublgins range from 5% ~ 80%. All proportions expressed herein are on a weight/weight basis.
Claims
1. A composition comprising a combination of extract of tea and a mixture of fatty acids obtained from natural products.
. The composition of claim 1 wherein the tea is selected from the group consisting of green tea and black tea.
3. The composition -of claim 1 wherein the fatt acid is obtained from saw palmetto extract.
4. the composition of claim 1 hsc contains an anti-prostate disease effective amount of a compound having the structure:
5. a compound having the structure:
6. A method for making the composition of claim 1 comprising extracting tea and saw palmetto, respectively, with a solvent and combining the thus obtained extracts.
7. A method for m king the composition of claim 1 comprising reacting an extract of tea with f¾ity acids at a temperature and for a time sufficient to produce an ester therefrom:.
8. A met od for the therapeutic treatment of a human diagnosed it prostate disease c m isng administering an anti-prostate disease effective amount of the composition of clam 1 to the human.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705280P | 2012-09-25 | 2012-09-25 | |
| US61/705,280 | 2012-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2014052225A1 true WO2014052225A1 (en) | 2014-04-03 |
Family
ID=50388887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2013/061143 WO2014052225A1 (en) | 2012-09-25 | 2013-09-23 | Composition for prostatic hyperplasia and prostate cancer |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2014052225A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104189690A (en) * | 2014-08-22 | 2014-12-10 | 兰州古驰生物科技有限公司 | Traditional Chinese medicine preparation for relieving male prostatitis symptoms and proliferation |
| EP3720462A4 (en) * | 2017-10-19 | 2021-12-22 | Yale University | Inhibition of androgen receptor by extracts of medicinal herbs and compositions thereof |
| CN114377107A (en) * | 2022-01-14 | 2022-04-22 | 完美（广东）日用品有限公司 | Application of sea-buckthorn seed meal protein peptide in preparation of medicine for preventing and treating prostatic hyperplasia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011123942A1 (en) * | 2010-04-08 | 2011-10-13 | Genesis Group Inc. | Fatty acid derivatives of catechins and methods of their use |
| WO2012061790A1 (en) * | 2010-11-04 | 2012-05-10 | Genyous Biomed International | Combination therapy for prostate cancer using botanical compositions and bicalutamide |
| US8221803B1 (en) * | 2007-06-25 | 2012-07-17 | OncoNatural Solutions, Inc. | Composition for prostate health |
-
2013
- 2013-09-23 WO PCT/US2013/061143 patent/WO2014052225A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8221803B1 (en) * | 2007-06-25 | 2012-07-17 | OncoNatural Solutions, Inc. | Composition for prostate health |
| WO2011123942A1 (en) * | 2010-04-08 | 2011-10-13 | Genesis Group Inc. | Fatty acid derivatives of catechins and methods of their use |
| WO2012061790A1 (en) * | 2010-11-04 | 2012-05-10 | Genyous Biomed International | Combination therapy for prostate cancer using botanical compositions and bicalutamide |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104189690A (en) * | 2014-08-22 | 2014-12-10 | 兰州古驰生物科技有限公司 | Traditional Chinese medicine preparation for relieving male prostatitis symptoms and proliferation |
| EP3720462A4 (en) * | 2017-10-19 | 2021-12-22 | Yale University | Inhibition of androgen receptor by extracts of medicinal herbs and compositions thereof |
| US11839639B2 (en) | 2017-10-19 | 2023-12-12 | Yale University | Inhibition of androgen receptor by extracts of medicinal herbs and compositions thereof |
| CN114377107A (en) * | 2022-01-14 | 2022-04-22 | 完美（广东）日用品有限公司 | Application of sea-buckthorn seed meal protein peptide in preparation of medicine for preventing and treating prostatic hyperplasia |
| CN114377107B (en) * | 2022-01-14 | 2023-09-05 | 完美（广东）日用品有限公司 | Application of sea buckthorn seed meal protein peptide in preparation of medicine for preventing and treating prostatic hyperplasia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8668944B2 (en) | Topical oil for treating physical ailments and method for making and applying the same | |
| JP2019523307A (en) | Method for preparing active extract and its application | |
| JP5137457B2 (en) | Stem cell growth factor expression increase inhibitor | |
| WO2010150245A1 (en) | Pharmaceutical and cosmeceutical compositions containing cannabis flower and seed extracts | |
| Lee et al. | Inhibitory effect of Cinnamomum osmophloeum Kanehira ethanol extracts on melanin synthesis via repression of tyrosinase expression | |
| TWI757246B (en) | Composition for topical application comprising dimethyl isosorbide, a polyol, and a phenolic or polyphenolic antioxidant | |
| JP2011105644A (en) | Melanin uptake inhibitor | |
| JP5041569B2 (en) | Tyrosinase activity inhibitor, whitening agent and skin cosmetic | |
| KR20070119296A (en) | Agent having effects of skin aging resister and skin whitening, manufactured using extract of pine tree as its main ingredient | |
| WO2014052225A1 (en) | Composition for prostatic hyperplasia and prostate cancer | |
| KR100478136B1 (en) | Extracts derived from plant that have anti-oxidation activity | |
| JP2013151451A (en) | Antioxidation/antiallergic agent containing extract of impatiens | |
| CN110859788B (en) | Tanaka composition and preparation method and application thereof | |
| KR101817941B1 (en) | Cosmetic compositions for skin-improvement having anti-atopic efficacy comprising Rubus crataegifolius leaf extraction as an efficient component | |
| EP3082464B1 (en) | Composition comprising grape extracts, the extraction method and its uses | |
| CN101411733B (en) | Method for extracting fresh pomegranate bark antioxidants | |
| KR101869763B1 (en) | Composition for preventing and curing dermatophytosis | |
| JP2007314462A (en) | External preparation | |
| KR20160081205A (en) | Composition comprising extract of hydrangea serrata for preventing and improving obesity | |
| KR102176618B1 (en) | Composition comprising extract of zea mays linne | |
| EP3858370A1 (en) | Composition for alleviating fatigue or enhancing exercise capability comprising angelica gigas extract, cnidii rhizoma extract, and paeonia japonica extract | |
| KR101484685B1 (en) | Composition comprising Angelica keiskei extract as active ingredient | |
| JP5896618B2 (en) | Melanin production inhibitor | |
| JP2015086168A (en) | Lipase inhibitor, and skin cosmetic for sebum control | |
| KR102145079B1 (en) | Compounds from the fruits of acrocomia crispa and acrocomia aculata against inflammation and oxidative stress |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13841109 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 13841109 Country of ref document: EP Kind code of ref document: A1 |